

Pharmacy

PRIOR AUTHORIZATION FORM

Last Reviewed: January 2012

Last Updated: July 2011

For Prior Authorization, please fax to: (877) 974-4411 toll free, or (616) 942-8206

This form applies to: Commercial Plan Medicaid Plan Medicare Plan

Tyvaso[®] (treprostinil)

URGENT (life threatening)

Non-Urgent (standard review)

A claim involving "urgent care" applies when the standard review time will seriously jeopardize the life or health of the member, or subject the member to severe pain that cannot be managed without the care or treatment requested in the subject of this request. **Priority Health averages between 1 and 3 business days for our standard review response time.**

Member Information

Member Name:	Member No.:
DOB:	Gender:
Member's PCP:	

Provider Information

Provider Name:	
Office Contact Name:	Provider Phone:
Provider NPI:	Provider Fax:
Provider Address:	

Provider Signature

Date

PRODUCT INFORMATION

- Tyvaso[®] 1.74 mg/2.9 mL solution for inhalation
 Tyvaso[®] Starter Kit 1.74 mg/2.9 mL solution for inhalation
 Tyvaso[®] Refill Kit 1.74 mg/2.9 mL solution for inhalation

Start Date: _____ **Dosing frequency:** _____

PRIORITY HEALTH PRECERTIFICATION REQUIREMENTS

Authorization for Tyvaso[®] (treprostinil) requires the following information to certify:

To certify this request, all of the following criteria must be met:

1. The medication is being used only for pulmonary arterial hypertension (PAH) for improvement of exercise capacity and to delay clinical worsening.
2. The patient's PAH classification meets World Health Organization Group 1 criteria with New York Heart Association (NYHA) Class III symptoms.

PRIORITY HEALTH PRECERTIFICATION DOCUMENTATION IS REQUIRED FOR REIMBURSEMENT

Authorization for Tyvaso[®] (treprostinil) requires the following information to certify:

1. What is the patient's diagnosis?

- a. Pulmonary arterial hypertension
b. Other: _____

Rationale for use: _____

Note: Authorization for indications not approved by the Food and Drug Administration (FDA) or recognized in CMS-accepted compendia (e.g. DrugDex, AHFS, and also Clinical Pharmacology for oncology indications only) require supporting evidence for coverage. Please provide two published peer-reviewed literature articles supporting the drug's use for the identified indication.

2. What is the patient's WHO classification of PAH?

- a. Group 1

- 1.1 Idiopathic PAH
1.2 Heritable
 1.2.1 BMPR2
 1.2.2 ALK1, endoglin
 1.2.3 Unknown
1.3 Drug- and toxin-induced
1.4 Associated with
 1.4.1 connective tissue disorder
 1.4.2 HIV infection
 1.4.3 Portal hypertension
 1.4.4 Congenital heart disease
 1.4.5 Schistosomiasis
 1.4.6 Chronic hemolytic anemia
1.5 Persistent pulmonary hypertension of the newborn

- b. Group 2 (Tyvaso[®] is not covered)
c. Group 3 (Tyvaso[®] is not covered)
d. Group 4 (Tyvaso[®] is not covered)
e. Group 5 (Tyvaso[®] is not covered)

3. Does the patient display New York Heart Association (NYHA) Class III symptoms?

- a. Yes

b. No – Rationale for use: _____

DOSING INFORMATION

- 18 to 54 mcg, administered as 3 to 9 breaths 4 times daily during waking hours
- The maximum daily dose is 216 mcg
- The safety and efficacy of Tyvaso in pediatric patients has not been established

*** All fields must be complete and legible for Prior Authorization Review***

Please fax this request to: (877)974-4411 toll free or (616)942-8206

YOUR OFFICE WILL RECEIVE A RESPONSE VIA FAX